GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (HKSE:01177) » Definitions » EV-to-FCF

Sino Biopharmaceutical (HKSE:01177) EV-to-FCF : 10.29 (As of May. 01, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Sino Biopharmaceutical EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sino Biopharmaceutical's Enterprise Value is HK$49,075 Mil. Sino Biopharmaceutical's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$4,771 Mil. Therefore, Sino Biopharmaceutical's EV-to-FCF for today is 10.29.

The historical rank and industry rank for Sino Biopharmaceutical's EV-to-FCF or its related term are showing as below:

HKSE:01177' s EV-to-FCF Range Over the Past 10 Years
Min: 10.29   Med: 27.44   Max: 53.32
Current: 10.29

During the past 13 years, the highest EV-to-FCF of Sino Biopharmaceutical was 53.32. The lowest was 10.29. And the median was 27.44.

HKSE:01177's EV-to-FCF is ranked worse than
61.58% of 393 companies
in the Biotechnology industry
Industry Median: 4.47 vs HKSE:01177: 10.29

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-01), Sino Biopharmaceutical's stock price is HK$2.70. Sino Biopharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.138. Therefore, Sino Biopharmaceutical's PE Ratio for today is 19.57.


Sino Biopharmaceutical EV-to-FCF Historical Data

The historical data trend for Sino Biopharmaceutical's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical EV-to-FCF Chart

Sino Biopharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.00 35.65 25.28 18.04 15.09

Sino Biopharmaceutical Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.28 - 18.04 - 15.09

Competitive Comparison of Sino Biopharmaceutical's EV-to-FCF

For the Biotechnology subindustry, Sino Biopharmaceutical's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sino Biopharmaceutical's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's EV-to-FCF falls into.



Sino Biopharmaceutical EV-to-FCF Calculation

Sino Biopharmaceutical's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=49074.646/4771.094
=10.29

Sino Biopharmaceutical's current Enterprise Value is HK$49,075 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sino Biopharmaceutical's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$4,771 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sino Biopharmaceutical  (HKSE:01177) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Sino Biopharmaceutical's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.70/0.138
=19.57

Sino Biopharmaceutical's share price for today is HK$2.70.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sino Biopharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.138.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Sino Biopharmaceutical EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Sino Biopharmaceutical (HKSE:01177) Business Description

Traded in Other Exchanges
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.

Sino Biopharmaceutical (HKSE:01177) Headlines

No Headlines